Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
Highlights CD40 expression correlates with the type I anti-tumor response and better survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RAS mut melanoma compared to nevi. RAS mutation correlates with reduced CD40 expression in malignant...
Main Authors: | Chi Yan, Ann Richmond |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-11-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12943-021-01442-3 |
Similar Items
-
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
by: David L. Bajor, et al.
Published: (2018-10-01) -
Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis
by: Lu Zhao, et al.
Published: (2021-12-01) -
Key questions about the checkpoint blockade-are microRNAs an answer?
by: Mihnea Dragomir, et al.
Published: (2018-06-01) -
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
by: Maria Georganaki, et al.
Published: (2018-12-01) -
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
by: Soumaya Karaki, et al.
Published: (2016-11-01)